Shopping Cart
Remove All
Your shopping cart is currently empty
Firivumab (CT-P22; CT120), a human IgG1 monoclonal antibody targeting influenza A virus hemagglutinin (Anti-IAV HA), demonstrates neutralization capabilities against multiple strains including H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2, and H12N7. It has also shown to protect mice from the H1N1 virus [1] [2] [3].
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | 2-4 weeks | 2-4 weeks | |
| 5 mg | $622 | 2-4 weeks | 2-4 weeks | |
| 10 mg | $996 | 2-4 weeks | 2-4 weeks |
| Description | Firivumab (CT-P22; CT120), a human IgG1 monoclonal antibody targeting influenza A virus hemagglutinin (Anti-IAV HA), demonstrates neutralization capabilities against multiple strains including H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2, and H12N7. It has also shown to protect mice from the H1N1 virus [1] [2] [3]. |
| Reactivity | Virus |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Cas No. | 1443004-15-6 |
| Storage | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.